> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Review Period Set for Pomalyst
- URL: https://www.fdaweb.com/review-period-set-for-pomalyst/
- Published: 2016-06-10T12:00:00.000Z
- Updated: 2026-09-14T21:09:01.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5135908

*Federal Register* Notice: FDA has determined the regulatory review period for Celgene Corp.'s Pomalyst (pomalidomide) is 3,716 days for extending a patent which claims the human drug product. Pomalyst is indicated for treating patients with multiple myeloma who have received at least two prior therapies including lenalidomide and bortezomib and have demonstrated disease progression on or within 60 days of completion of last therapy. To view this notice, click [here](https://www.gpo.gov/fdsys/pkg/FR-2016-06-10/pdf/2016-13796.pdf?ref=fdaweb.com).